title: Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
abstract: A 2-month interruption of only nonnucleoside reverse transcriptase inhibitors (NNRTIs) for patients carrying mutations associated with resistance to NNRTIs was followed by no change in either viral load or CD4 cell counts. These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases.
authors.affiliation: Department of Virology, Pitié-Salpêtrière Hospital. Department of Pharmacology, Bichat Hospital, Paris, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Wirden
authors.forename: Anne
authors.initials: A
authors.lastname: Simon
authors.forename: Luminita
authors.initials: L
authors.lastname: Schneider
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
authors.forename: Luc
authors.initials: L
authors.lastname: Paris
authors.forename: Anne Genevieve
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Constance
authors.initials: C
authors.lastname: Delaugerre
authors.forename: Mayeule
authors.initials: M
authors.lastname: Legrand
authors.forename: Serge
authors.initials: S
authors.lastname: Herson
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000187:drug effects / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D009154:Mutation; D019829:Nevirapine / Q000008:administration & dosage / Q000494:pharmacology; D010078:Oxazines / Q000008:administration & dosage / Q000494:pharmacology; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D019562:Viral Load
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D054303:HIV Reverse Transcriptase; C098320:efavirenz